Press Needle Acupuncture for Pain in Lung Cancer Patients
Tests press needle acupuncture with standard care for pain in adults with lung cancer.
Plain-language title generated from the registry record
Registry title: Press Needle Acupuncture for Pain and Quality of Life in Lung Cancer Patients
Key facts
- Where
- Jakarta Pusat, IndonesiaSee the site
Where in Indonesia
- Universitas IndonesiaJakarta Pusat, IndonesiaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Universitas Indonesia
- Trial code
- NCT07112950
- Record updated
- 8 August 2025
- Original description
The purpose of this clinical trial is to evaluate the effect of press needle acupuncture on pain management and quality of life improvement in patients with lung cancer.Read full original descriptionShow less
The Effect of Press Needle Acupuncture on Pain Reduction and Quality of Life Improvement in Lung Cancer Patients
The purpose of this clinical trial is to evaluate the effect of press needle acupuncture on pain management and quality of life improvement in patients with lung cancer.
The main question this study aims to answer is:
Does press needle acupuncture, when combined with standard therapy, provide better pain relief and quality of life improvement in lung cancer patients compared to standard therapy alone?
Researchers will compare press needle acupuncture to sham acupuncture to determine whether press needle acupuncture is more effective in reducing pain and improving quality of life.
Participants will:
Receive either press needle acupuncture or sham press needle acupuncture for 7 days
Visit the clinic once a week for examination and evaluation
Record improvements in pain intensity in a pain diary and assess quality of life using a quality of life questionnaire
Inclusion: Patients with a confirmed diagnosis of lung cancer through histopathology or radiology; Lung cancer patients aged over 18 years; Stage III-IV lung cancer patients receiving therapy at Dr. Cipto Mangunkusumo National General Hospital (RSUPN) and Tangerang District General Hospital (RSUD Kabupaten Tangerang); Patients with a VAS score >10 mm for baseline pain and >40 mm during breakthrough pain; Willing to participate in the study until completion by signing the informed consent form.
Exclusion: Lung cancer patients with deteriorating general condition; Presence of wounds or infections at the press needle insertion site; History of allergy to stainless steel materials; Patients with blood clotting disorders: platelet count <50,000/μL, ANC <1000/mm³, or patients undergoing anticoagulant therapy with INR >2.142.